Fsgs clinical trials

Explore recruiting fsgs clinical trials.

Recruiting fsgs studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Fsgs trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A parallel-group treatment, Phase 2a, multicenter, randomized, double-blind, placebo-controlled umbrella study to evaluate the efficacy and safety of frexalimab, brivekimig and rilzabrutinib in participants aged 16 to 75 years with primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD)

Hungary, Portugal, Italy, France, Germany, Spain +5 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

France, Belgium, Netherlands, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of DMX-200 in patients with focal segmental glomerulosclerosis (FSGS) who are receiving an angiotensin II receptor blocker (ARB)

France, Spain, Denmark, Germany, Italy, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Randomized, Multicenter, Double-blind, Parallel, Active-control Study of the Effects of Sparsentan, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, on Renal Outcomes in Patients with Primary Focal Segmental Glomerulosclerosis (FSGS)

Germany, Belgium, France, Spain, Czechia, Croatia +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Effects of the ABCA1 inducer R3R01 on albuminuria levels in diabetic kidney disease

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants

Germany, Croatia, Poland, Sweden, Portugal, Netherlands +9 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Fsgs trials by city

Fsgs in Toronto Fsgs in Vancouver Fsgs in Montreal Fsgs in Calgary Fsgs in Edmonton Fsgs in Ottawa Fsgs in Winnipeg Fsgs in Quebec City Fsgs in Hamilton Fsgs in Kitchener Fsgs in London Fsgs in Halifax Fsgs in New York Fsgs in Los Angeles Fsgs in Chicago Fsgs in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease